Association of inflammatory markers in depressed patients with cognitive dysfunctio

• Conditions: F33; F31; Recurrent depressive disorder; Bipolar affective disorder

• Registration Number: DRKS00023311
• Lead Sponsor: Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Regensburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2020-03-01
• Study Start: 2020-10-20
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

patients aged between 18 and 60 who are able to give consent
inpatient treatment due to a depressive episode (ICD-10 F31, F32, F33; HAMD-21: 18-30)
after written informed consent

Exclusion Criteria

• pregnant or brest-feeding women
• drug or alcohol dependence
• dementia
• depressive episode secondary of a somatic/neurological illness or substance abuse
• severe somatic or neurological illness which can impair results (e.g. Morbus Cushing, rheumathoid illness)
• other psychiatric comorbidities
• The patient cannot understand the scope of the study and is not capable of giving consent.
• admission to hospital not voluntary
• regular intake of steroids or non-steroidal antiphlogistics (NSAID)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CCR5 level: baseline and after 5 weeks (W5)<br>CANTAB scores: baseline and after 5 weeks (W5)<br>HAMD-21 sum scores: baseline and after 5 weeks (W5)<br><br><br>We want to assess if their is a clinical improvement after 5 weeks of treatment (HAMD-21) and if this is in relation to an improvement of depression-associated cognitive dysfunction (CANTAB) and if there is a correlation with CCR5 levels, which has already been shown to influence learning and memory in animal models.

Secondary Outcome Measures

Name	Time	Method
CCL5 levels<br>IL-1 beta levels<br>TNF-alpha levels<br>IL-6 levels<br>BDI scores